Search Results - "Andrew, D.J"

Advances in Risk Classification and Treatment Strategies for Neuroblastoma by Pinto, Navin R, Applebaum, Mark A, Volchenboum, Samuel L, Matthay, Katherine K, London, Wendy B, Ambros, Peter F, Nakagawara, Akira, Berthold, Frank, Schleiermacher, Gudrun, Park, Julie R, Valteau-Couanet, Dominique, Pearson, Andrew D J, Cohn, Susan L

“…Risk-based treatment approaches for neuroblastoma have been ongoing for decades. However, the criteria used to define risk in various institutional and…”
Get full text

New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK by BARONE, Giuseppe, ANDERSON, John, PEARSON, Andrew D. J, PETRIE, Kevin, CHESLER, Louis

“…Clinical outcome remains poor in patients with high-risk neuroblastoma, in which chemoresistant relapse is common following high-intensity conventional…”
Get full text

Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project by Sokol, Elizabeth, Desai, Ami V, Applebaum, Mark A, Valteau-Couanet, Dominique, Park, Julie R, Pearson, Andrew D J, Schleiermacher, Gudrun, Irwin, Meredith S, Hogarty, Michael, Naranjo, Arlene, Volchenboum, Samuel, Cohn, Susan L, London, Wendy B

“…The Children's Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and…”
Get full text

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report by COHN, Susan L, PEARSON, Andrew D. J, MOSSERI, Veronique, SIMON, Thorsten, GARAVENTA, Alberto, CASTEL, Victoria, MATTHAY, Katherine K, LONDON, Wendy B, MONCLAIR, Tom, AMBROS, Peter F, BRODEUR, Garrett M, FALDUM, Andreas, HERO, Barbara, IEHARA, Tomoko, MACHIN, David

“…Because current approaches to risk classification and treatment stratification for children with neuroblastoma (NB) vary greatly throughout the world, it is…”
Get full text

Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project by Vo, Kieuhoa T, Matthay, Katherine K, Neuhaus, John, London, Wendy B, Hero, Barbara, Ambros, Peter F, Nakagawara, Akira, Miniati, Doug, Wheeler, Kate, Pearson, Andrew D J, Cohn, Susan L, DuBois, Steven G

“…Neuroblastoma (NB) is a heterogeneous tumor arising from sympathetic tissues. The impact of primary tumor site in influencing the heterogeneity of NB remains…”
Get full text

Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study by Holmes, Keith, Pötschger, Ulrike, Pearson, Andrew D J, Sarnacki, Sabine, Cecchetto, Giovanni, Gomez-Chacon, Javier, Squire, Roly, Freud, Enrique, Bysiek, Adam, Matthyssens, Lucas E, Metzelder, Martin, Monclair, Tom, Stenman, Jakob, Rygl, Michal, Rasmussen, Lars, Joseph, Jean-Marc, Irtan, Sabine, Avanzini, Stefano, Godzinski, Jan, Björnland, Kristin, Elliott, Martin, Luksch, Roberto, Castel, Victoria, Ash, Shifra, Balwierz, Walentyna, Laureys, Geneviève, Ruud, Ellen, Papadakis, Vassilios, Malis, Josef, Owens, Cormac, Schroeder, Henrik, Beck-Popovic, Maja, Trahair, Toby, Forjaz de Lacerda, Ana, Ambros, Peter F, Gaze, Mark N, McHugh, Kieran, Valteau-Couanet, Dominique, Ladenstein, Ruth Lydia

“…To evaluate the impact of surgeon-assessed extent of primary tumor resection on local progression and survival in patients in the International Society of…”
Get full text

Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project by LONDON, Wendy B, CASTEL, Victoria, MATTHAY, Katherine K, MONCLAIR, Tom, AMBROS, Peter F, PEARSON, Andrew D. J, COHN, Susan L, BERTHOLD, Frank, NAKAGAWARA, Akira, LADENSTEIN, Ruth L, IEHARA, Tomoko

“…Survival after neuroblastoma relapse is poor. Understanding the relationship between clinical and biologic features and outcome after relapse may help in…”
Get full text

The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report by MONCLAIR, Tom, BRODEUR, Garrett M, VON SCHWEINITZ, Dietrich, SIMON, Thorsten, COHN, Susan L, PEARSON, Andrew D. J, AMBROS, Peter F, BRISSE, Hervé J, CECCHETTO, Giovanni, HOLMES, Keith, KANEKO, Michio, LONDON, Wendy B, MATTHAY, Katherine K, NUCHTERN, Jed G

“…The International Neuroblastoma Risk Group (INRG) classification system was developed to establish a consensus approach for pretreatment risk stratification…”
Get full text

Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database by Morgenstern, Daniel A, London, Wendy B, Stephens, Derek, Volchenboum, Samuel L, Simon, Thorsten, Nakagawara, Akira, Shimada, Hiroyuki, Schleiermacher, Gudrun, Matthay, Katherine K, Cohn, Susan L, Pearson, Andrew D.J, Irwin, Meredith S

“…Abstract Neuroblastoma is a childhood cancer with remarkably divergent tumour behaviour and the presence of metastatic disease is a powerful predictor of…”
Get full text

Implementation of mechanism of action biology-driven early drug development for children with cancer by Pearson, Andrew D.J, Herold, Ralf, Rousseau, Raphaël, Copland, Chris, Bradley-Garelik, Brigid, Binner, Debbie, Capdeville, Renaud, Caron, Hubert, Carleer, Jacqueline, Chesler, Louis, Geoerger, Birgit, Kearns, Pamela, Marshall, Lynley V, Pfister, Stefan M, Schleiermacher, Gudrun, Skolnik, Jeffrey, Spadoni, Cesare, Sterba, Jaroslav, van den Berg, Hendrick, Uttenreuther-Fischer, Martina, Witt, Olaf, Norga, Koen, Vassal, Gilles

“…Abstract An urgent need remains for new paediatric oncology drugs to cure children who die from cancer and to reduce drug-related sequelae in survivors. In…”
Get full text

Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors by Skinner, Roderick, Parry, Annie, Price, Lisa, Cole, Michael, Craft, Alan W, Pearson, Andrew D.J

“…Abstract Purpose The long-term outcome of platinum-induced nephrotoxicity is unknown. This prospective single-centre longitudinal cohort study evaluated…”
Get full text

Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project by Moroz, Veronica, Machin, David, Faldum, Andreas, Hero, Barbara, Iehara, Tomoko, Mosseri, Veronique, Ladenstein, Ruth, Bernardi, Bruno De, Rubie, Hervé, Berthold, Frank, Matthay, Katherine K, Monclair, Tom, Ambros, Peter F, Pearson, Andrew D.J, Cohn, Susan L, London, Wendy B

“…Abstract Purpose Increasing age has been an adverse risk factor in children with neuroblastoma (NB) since the 1970’s, with a 12-month age-at-diagnosis cut-off…”
Get full text

Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents by Pearson, Andrew D.J., Zwaan, C.Michel, Kolb, E.Anders, Karres, Dominik, Guillot, Julie, Kim, Su Young, Marshall, Lynley, Tasian, Sarah K., Smith, Malcolm, Cooper, Todd, Adamson, Peter C., Barry, Elly, Benettaib, Bouchra, Binlich, Florence, Borgman, Anne, Brivio, Erica, Capdeville, Renaud, Delgado, David, Faller, Douglas, Fogelstrand, Linda, Fraenkel, Paula Goodman, Hasle, Henrik, Heenen, Delphine, Kaspers, Gertjan, Kieran, Mark, Klusmann, Jan-Henning, Lesa, Giovanni, Ligas, Franca, Mappa, Silvia, Mohamed, Hesham, Moore, Andrew, Morris, Joan, Nottage, Kerri, Reinhardt, Dirk, Scobie, Nicole, Simko, Stephen, Winkler, Thomas, Norga, Koen, Reaman, Gregory, Vassal, Gilles

“…The current standard-of-care for front-line therapy for acute myeloid leukaemia (AML) is a combination of an anthracycline with cytarabine resulting in…”
Get full text

Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without MYCN Gene Amplification by DE BERNARDI, Bruno, GERRARD, Mary, BRICHARD, Benédicte, COUTURIER, Jerome, ELLERSHAW, Caroline, MUNZER, Caroline, BRUZZI, Paolo, MICHON, Jean, PEARSON, Andrew D. J, BONI, Luca, RUBIE, Hervé, CANETE, Adela, DI CATALDO, Andrea, CASTEL, Victoria, FORJAZ DE LACERDA, Ana, LADENSTEIN, Ruth, RUUD, Ellen

“…On the assumption that most infants with disseminated neuroblastoma without MYCN amplification (MYCNA) have a favorable prognosis, two concomitant prospective…”
Get full text

Phase 1 study of dalotuzumab monotherapy and ridaforolimus–dalotuzumab combination therapy in paediatric patients with advanced solid tumours by Frappaz, Didier, Federico, Sara M, Pearson, Andrew D.J, Gore, Lia, Macy, Margaret E, DuBois, Steven G, Aerts, Isabelle, Iannone, Robert, Geschwindt, Ryan, Van Schanke, Arne, Wang, Rui, Geoerger, Birgit

“…Abstract Aim Dalotuzumab is a highly specific, humanised immunoglobulin G1 monoclonal antibody against insulin-like growth factor receptor 1. This multicenter…”
Get full text

Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study by Carceller, Fernando, Bautista, Francisco J, Jiménez, Irene, Hladun-Álvaro, Raquel, Giraud, Cécile, Bergamaschi, Luca, Dandapani, Madhumita, Aerts, Isabelle, Doz, François, Frappaz, Didier, Casanova, Michela, Morland, Bruce, Hargrave, Darren R, Marshall, Lynley V, Vassal, Gilles, Pearson, Andrew D.J, Geoerger, Birgit, Moreno, Lucas

“…Abstract Objectives Dose-finding trials are fundamental to develop novel drugs for children and adolescents with advanced cancer. It is crucial to maximise…”
Get full text

Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastoma Without MYCN Amplification: Results of the Prospective INES 99.1 by RUBIE, Hervé, DE BERNARDI, Bruno, BROCK, Penelope, CASTEL, Victoria, VALTEAU-COUANET, Dominique, HOLMES, Keith, DI CATALDO, Andrea, BRICHARD, Bénédicte, MOSSERI, Véronique, MARQUEZ, Catalina, PLANTAZ, Dominique, BONI, Luca, GERRARD, Mary, MICHON, Jean, CANETE, Adela, LADENSTEIN, Ruth, COUTURIER, Jérôme, AMBROS, Peter, MUNZER, Caroline, PEARSON, Andrew D. J, GARAVENTA, Alberto

“…To evaluate the efficacy of low-dose chemotherapy in infants with nonmetastatic and unresectable neuroblastoma (NB) without MYCN amplification. Infants with…”
Get full text

Significance of MYCN Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group Database by BAGATELL, Rochelle, BECK-POPOVIC, Maja, LONDON, Wendy B, YANG ZHANG, PEARSON, Andrew D. J, MATTHAY, Katherine K, MONCLAIR, Tom, AMBROS, Peter F, COHN, Susan L

“…Treatment of patients with localized neuroblastoma with unfavorable biologic features is controversial. To evaluate the outcome of children with low-stage…”
Get full text

Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age by TAGGART, Denah R, LONDON, Wendy B, MATTHAY, Katherine K, LOU SCHMIDT, Mary, DUBOIS, Steven G, MONCLAIR, Tom F, NAKAGAWARA, Akira, DE BERNARDI, Bruno, AMBROS, Peter F, PEARSON, Andrew D. J, COHN, Susan L

“…Patients with neuroblastoma younger than 12 months of age with a 4S pattern of disease (metastases limited to liver, skin, bone marrow) have better outcomes…”
Get full text

Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project by Meany, Holly J., London, Wendy B., Ambros, Peter F., Matthay, Katherine K., Monclair, Tom, Simon, Thorsten, Garaventa, Alberto, Berthold, Frank, Nakagawara, Akira, Cohn, Susan L., Pearson, Andrew D.J., Park, Julie R.

“…Background International Neuroblastoma Staging System (INSS) Stage 3 neuroblastoma is a heterogeneous disease. Data from the International Neuroblastoma Risk…”
Get full text